Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3859MR)

This product GTTS-WQ3859MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3859MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9188MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN853
GTTS-WQ9209MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ9225MR IVTScrip™ mRNA-Anti-MS4A1, IMMU-106(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-106
GTTS-WQ3801MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ8194MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ10163MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ10505MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY3002813
GTTS-WQ2345MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AME-133v
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW